SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001558370-22-009242
Filing Date
2022-05-23
Accepted
2022-05-23 06:01:48
Documents
13
Period of Report
2022-05-21
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K kala-20220521x8k.htm   iXBRL 8-K 44714
2 EX-2.1 kala-20220521xex2d1.htm EX-2.1 736225
  Complete submission text file 0001558370-22-009242.txt   1023263

Data Files

Seq Description Document Type Size
3 EX-101.SCH kala-20220521.xsd EX-101.SCH 3150
4 EX-101.LAB kala-20220521_lab.xml EX-101.LAB 15926
5 EX-101.PRE kala-20220521_pre.xml EX-101.PRE 10061
7 EXTRACTED XBRL INSTANCE DOCUMENT kala-20220521x8k_htm.xml XML 4870
Mailing Address 1167 MASSACHUSETTS AVENUE ARLINGTON MA 02476
Business Address 1167 MASSACHUSETTS AVENUE ARLINGTON MA 02476 781-996-5252
Kala Pharmaceuticals, Inc. (Filer) CIK: 0001479419 (see all company filings)

IRS No.: 270604595 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38150 | Film No.: 22949474
SIC: 2834 Pharmaceutical Preparations